Literature DB >> 27269058

Evaluation of different heterologous prime-boost immunization strategies against Babesia bovis using viral vectored and protein-adjuvant vaccines based on a chimeric multi-antigen.

José Manuel Jaramillo Ortiz1, María Paula Molinari1, María José Gravisaco1, Martina Soledad Paoletta1, Valeria Noely Montenegro1, Silvina Elizabeth Wilkowsky1.   

Abstract

Protection against the intraerythrocytic bovine parasite Babesia bovis requires both humoral and cellular immune responses. Therefore, tailored combinations of immunogens targeted at both arms of the immune system are strategies of choice to pursue sterilizing immunity. In this study, different heterologous prime-boost vaccination schemes were evaluated in mice to compare the immunogenicity induced by a recombinant adenovirus, a modified vaccinia Ankara vector or a subunit vaccine all expressing a chimeric multi-antigen. This multi-antigen includes the immunodominant B and T cell epitopes of three B. bovis proteins: Merozoite Surface Antigen - 2c (MSA-2c), Rhoptry Associated Protein - 1 (RAP-1) and Heat Shock Protein 20 (HSP20). Both priming with the adenovirus or recombinant multi-antigen and boosting with the modified vaccinia Ankara vector achieved a high degree of activation of TNFα and IFNγ-secreting CD4(+) and CD8(+) specific T cells 60days after the first immunization. High titers of specific IgG antibodies were also detected at the same time point and lasted up to day 120 of the first immunization. Only the adenovirus - MVA combination triggered a marked isotype skew for the IgG2a antibody subclass meanwhile for the other immune traits analyzed here, both vaccination schemes showed similar performances. The immunological characterization in the murine model of these rationally designed immunogens led us to propose that adenoviruses as well as the bacterially expressed multi-antigen are highly reliable primer candidates to be considered in future experiments in cattle to test protection against bovine babesiosis.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Babesia bovis; Boost immunizations; Heterologous prime; Recombinant multi-antigen; Viral vectored vaccines

Mesh:

Substances:

Year:  2016        PMID: 27269058     DOI: 10.1016/j.vaccine.2016.05.053

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Partial protection with a chimeric tetraspanin-leucine aminopeptidase subunit vaccine against Opisthorchis viverrini infection in hamsters.

Authors:  Luyen Thi Phung; Sujittra Chaiyadet; Nuttanan Hongsrichan; Javier Sotillo; Hang Dinh Thi Dieu; Canh Quang Tran; Paul J Brindley; Alex Loukas; Thewarach Laha
Journal:  Acta Trop       Date:  2020-01-25       Impact factor: 3.112

2.  Evaluation of a Major Surface Antigen of Babesia microti Merozoites as a Vaccine Candidate against Babesia Infection.

Authors:  Suqin Man; Yongfeng Fu; Yue Guan; Meng Feng; Ke Qiao; Xueping Li; Hongjian Gao; Xunjia Cheng
Journal:  Front Microbiol       Date:  2017-12-19       Impact factor: 5.640

3.  Development of an Indirect ELISA Based on a Recombinant Chimeric Protein for the Detection of Antibodies against Bovine Babesiosis.

Authors:  José Manuel Jaramillo Ortiz; Valeria Noely Montenegro; Sofía Ana María de la Fournière; Néstor Fabián Sarmiento; Marisa Diana Farber; Silvina Elizabeth Wilkowsky
Journal:  Vet Sci       Date:  2018-01-23

4.  Humoral and Cell-Mediated Immune Response Validation in Calves after a Live Attenuated Vaccine of Babesia bigemina.

Authors:  Umber Rauf; Muhammad Suleman; Asadullah Abid; Hamna Jamil; Harish Menghwar; Aneela Zameer Durrani; Muhammad Imran Rashid; Haroon Akbar
Journal:  Pathogens       Date:  2020-11-11

Review 5.  Immune Response to Tick-Borne Hemoparasites: Host Adaptive Immune Response Mechanisms as Potential Targets for Therapies and Vaccines.

Authors:  Alessandra Torina; Valeria Blanda; Sara Villari; Antonio Piazza; Francesco La Russa; Francesca Grippi; Marco Pio La Manna; Diana Di Liberto; José de la Fuente; Guido Sireci
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.